World News: 14:00 GMT Tuesday 14th January 2020. [Rafael Pharmaceuticals, Inc. via Globe Newswire via SPi World News]
Cranbury, NJ, Jan. 14, 2020 (GLOBE NEWSWIRE) -- (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has reached an enrollment milestone of more than 250 patients in its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy. This significant milestone comes ahead of schedule, halfway to enrolling the total goal of 500 patients. The in sites across the United States, Israel, South Korea and France with plans to begin enrolling in other regions of Europe including Germany, Italy, and Belgium in early 2020.
“The speed at which patients are being enrolled into the trial is demonstrative of the tremendous need there is for effective treatments for metastatic pancreatic cancer and the hope people have in cancer metabolism,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “We are aiming to keep the momentum going so that we can not only provide hope, but ultimately, an effective treatment.”
The principal investigator on Rafael’s Phase 3 clinical trial for patients with pancreatic cancer is Philip A. Philip, M.D., Professor of Oncology at the .
“It is incredible to announce that we’ve reached 250 patients in this pivotal clinical trial for one of the deadliest cancers in the world,” said Dr. Philip. “Cancer metabolism is truly proving that it is a promising treatment for metastatic pancreatic cancer, and as we move into the new decade, I am hopeful that we will continue to see devimistat’s potential. I would like to thank all of the patients, their families and the doctors participating in this trial who have continued to help us reach these milestones.”
Globe Newswire: 14:00 GMT Tuesday 14th January 2020
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.